Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARA | P10276 | 10/20 | 0.53 |
| ▸ | RARB | P10826 | 10/20 | 0.48 |
| ▸ | RARG | P13631 | 9/20 | 0.48 |
| ▸ | RXRA | P19793 | 5/20 | 0.48 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.44 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.44 |
| ▸ | RXRB | P28702 | 2/20 | 0.42 |
| ▸ | RXRG | P48443 | 2/20 | 0.42 |
| ▸ | MTOR | P42345 | 1/20 | 0.41 |
| ▸ | CYP26A1 | O43174 | 2/20 | 0.40 |
| ▸ | CYP26B1 | Q9NR63 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9190385 | 0.80 | RARA (0.50) | RARARARBRARGRXRAABCB1 | |
| SCHEMBL7647113 | 0.79 | ABCB1 (0.69) | RARARARBRARGRXRAABCB1 | |
| SCHEMBL7877006 | 0.78 | RARB (0.64) | RARARARBRARGRXRARXRB | |
| SCHEMBL2095481 | 0.78 | RXRA (0.57) | RARARARBRARGRXRARXRB | |
| SCHEMBL9190873 | 0.77 | RARA (0.50) | RARARARBRARGRXRAABCB1 | |
| SCHEMBL10834477 | 0.77 | RARB (0.59) | RARARARBRARGRXRARXRB | |
| SCHEMBL9186798 | 0.76 | CYP3A4 (0.56) | RARARARBRARGRXRAABCB1 | |
| SCHEMBL5845401 | 0.73 | RARB (0.57) | RARARARBRARGRXRARXRB | |
| SCHEMBL9132923 | 0.73 | PDE10A (0.43) | RARARARBRARGRXRA | |
| SCHEMBL9484092 | 0.72 | RARB (0.62) | RARARARBRARGRXRARXRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5475017-A | Skin disorders, antitumor agents; side effect reduction | BASF AKTIENGESELLSCHAFT (DE) | 1995-12-12 | — | — | US | disclosed |
| EP-0382077-B1 | Diaryl-substituted heterocyclic compound, its preparation and medicaments and cosmetics made thereof | BASF AG (DE) | 1995-05-17 | — | — | EP | disclosed |
| US-5338749-A | Treating rheumatic or arthritic disorders | BASF AKTIENGESELLSCHAFT (DE) | 1994-08-16 | — | — | US | disclosed |
| US-5206242-A | Skin disorders | BASF AKTIENGESELLSCHAFT (DE) | 1993-04-27 | — | — | US | disclosed |
| US-5196532-A | Treatment of skin disorders | BASF AKTIENGESELLSCHAFT (DE) | 1993-03-23 | — | — | US | disclosed |
| US-5061705-A | Skin disorders | BASF AKTIENGESELLSCHAFT (DE) | 1991-10-29 | — | — | US | disclosed |
| EP-0382077-A2 | Diaryl-substituted heterocyclic compound, its preparation and medicaments and cosmetics made thereof | BASF Aktiengesellschaft (DE) | 1990-08-16 | — | — | EP | disclosed |